TuHURA Biosciences, Inc. reported that Highbridge Capital Management, LLC has become a significant holder of its common stock through warrants. Highbridge reports beneficial ownership of 6,060,608 shares of TuHURA common stock, all issuable upon exercise of warrants held by funds and accounts it advises.
This position represents 9.1% of TuHURA’s common stock, calculated using 60,720,508 shares outstanding as of December 10, 2025, after a recently completed offering and assuming warrant exercise. Highbridge has sole voting and dispositive power over these warrant shares and is filing as an investment adviser.
The filing states the securities were acquired and are held in the ordinary course of business, not with the purpose or effect of changing or influencing control of TuHURA. Highbridge Tactical Credit Master Fund, L.P., one of the advised funds, has rights over more than 5% of the outstanding shares.
MANUSO JAMES S J reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
List Alan reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
Hoffman Robert E. reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
TuHURA Biosciences, Inc. received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement because the consolidated closing bid has been below $1.00 per share for 35 consecutive business days as of January 28, 2026. The stock is not being immediately delisted, and the company has a 180-day grace period, until July 28, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days. If it still fails to comply, TuHURA may be eligible for a second 180-day period, potentially including measures such as a reverse stock split, and could also request a hearing to delay any suspension or delisting. The company states that the notice does not affect its business, operations, or SEC reporting, but it cautions that there is no assurance it will regain or maintain Nasdaq listing compliance.
TuHURA Biosciences, Inc. reported an insider equity award for its Chief Financial Officer, Dan Dearborn. On January 6, 2026, he was granted 273,696 options (right to buy common stock) with an exercise price of $0.73 per share, expiring on January 6, 2036. The options were acquired at no cost and are held directly. According to the footnote, this is a supplemental option grant to an option grant previously made in December 2025, and one-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.
TuHURA Biosciences, Inc. reported an insider equity award for its Chief Executive Officer and director, James A. Bianco. On January 6, 2026, he received an award of 610,332 stock options (options right to buy common stock) with an exercise price of $0.73 per share and an expiration date of January 6, 2036. The options were granted at no cost as a supplemental option grant to one previously made in December 2025.
According to the disclosure, one-third of these stock options become exercisable on the first, second, and third anniversary of January 6, 2025, creating a three-year vesting schedule. Following this grant, Bianco beneficially owns 610,332 derivative securities directly.
TuHURA Biosciences, Inc. (HURA) reported that its Chief Financial Officer, Dan Dearborn, received stock options to purchase 1,531,367 shares of common stock at an exercise price of $1.02 per share on 12/12/2025.
The options are held directly, expire on 12/12/2035, and cover 1,531,367 underlying shares, which is also the number of derivative securities beneficially owned after the transaction. One-third of the stock options becomes exercisable on each of the first, second, and third anniversaries of 12/12/2025, creating a three-year vesting schedule.
TuHURA Biosciences, Inc. insider James Bianco, the company’s chief executive officer and a director, reported acquiring stock options on 12/12/2025. The options give him the right to buy up to 3,414,891 shares of TuHURA common stock at an exercise price of $1.02 per share and are scheduled to expire on 12/12/2035.
According to the filing, these options were acquired in a single transaction coded "A" and had a reported price of $0 for the derivative security itself. A footnote explains that one-third of the options become exercisable on each of the first, second, and third anniversaries of December 12, 2025. Following this transaction, Bianco beneficially owns 3,414,891 stock options directly.
TuHURA Biosciences, Inc. reports that a previously registered offer and sale of up to 9,321,545 shares of its common stock will now be covered by its effective Form S-3 shelf registration statement. These shares consist of 4,570,629 shares of common stock sold in a June 2, 2025 private placement and 4,750,916 shares issuable upon exercise of related warrants, all originally registered on a Form S-1 resale registration statement.
The Form S-3 shelf registration statement (File No. 333-291239), initially filed on November 3, 2025, became effective on November 22, 2025 under Section 8(a) of the Securities Act. Under Section 415(a)(6), the earlier Form S-1 resale registration is deemed terminated, and the same selling securityholders may now offer the same shares from time to time under the new shelf registration.